

Kristiina M Huttunen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2957907/publications.pdf>

Version: 2024-02-01

80
papers

2,503
citations

236925

25
h-index

223800

46
g-index

82
all docs

82
docs citations

82
times ranked

3042
citing authors

#	ARTICLE	IF	CITATIONS
1	Prodrugsâ€”from Serendipity to Rational Design. <i>Pharmacological Reviews</i> , 2011, 63, 750-771.	16.0	410
2	Metformin â€” a Future Therapy for Neurodegenerative Diseases. <i>Pharmaceutical Research</i> , 2017, 34, 2614-2627.	3.5	187
3	Design, Synthesis and Brain Uptake of LAT1-Targeted Amino Acid Prodrugs of Dopamine. <i>Pharmaceutical Research</i> , 2013, 30, 2523-2537.	3.5	102
4	Amino acids as promoieties in prodrug design and development. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1370-1385.	13.7	100
5	L-Type amino acid transporter 1 as a target for drug delivery. <i>Pharmaceutical Research</i> , 2020, 37, 88.	3.5	97
6	Is Metformin â€” a Perfect Drug? Updates in Pharmacokinetics and Pharmacodynamics. <i>Current Pharmaceutical Design</i> , 2017, 23, 2532-2550.	1.9	69
7	Prodrugs - An Efficient Way to Breach Delivery and Targeting Barriers. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 2265-2287.	2.1	64
8	L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs. <i>Journal of Controlled Release</i> , 2017, 261, 93-104.	9.9	62
9	The First Bioreversible Prodrug of Metformin with Improved Lipophilicity and Enhanced Intestinal Absorption. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 4142-4148.	6.4	58
10	Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery. <i>Current Medicinal Chemistry</i> , 2008, 15, 2346-2365.	2.4	56
11	L-Type Amino Acid Transporter 1 (LAT1/Lat1)-Utilizing Prodrugs Can Improve the Delivery of Drugs into Neurons, Astrocytes and Microglia. <i>Scientific Reports</i> , 2019, 9, 12860.	3.3	53
12	Quantitative Insight into the Design of Compounds Recognized by the L-Type Amino Acid Transporterâ€”1 (LAT1). <i>ChemMedChem</i> , 2014, 9, 2699-2707.	3.2	52
13	A Selective and Slowly Reversible Inhibitor of L-Type Amino Acid Transporter 1 (LAT1) Potentiates Antiproliferative Drug Efficacy in Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 5740-5751.	6.4	52
14	L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 129, 99-109.	4.0	41
15	Determination of metformin and its prodrugs in human and rat blood by hydrophilic interaction liquid chromatography. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009, 50, 469-474.	2.8	40
16	Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure. <i>Neurochemical Research</i> , 2016, 41, 2797-2809.	3.3	38
17	L-Type amino acid transporter 1 (lat1)-mediated targeted delivery of perforin inhibitors. <i>International Journal of Pharmaceutics</i> , 2016, 498, 205-216.	5.2	34
18	Extract of <i>Aronia melanocarpa</i> -modified hemostasis: in vitro studies. <i>European Journal of Nutrition</i> , 2014, 53, 1493-1502.	3.9	32

#	ARTICLE	IF	CITATIONS
19	Systemic and Brain Pharmacokinetics of Perforin Inhibitor Prodrugs. <i>Molecular Pharmaceutics</i> , 2016, 13, 2484-2491.	4.6	32
20	Exploration of a Series of 5-Arylidene-2-thioxoimidazolidin-4-ones as Inhibitors of the Cytolytic Protein Perforin. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 9542-9555.	6.4	30
21	Studies towards biocompatibility of PAMAM dendrimers – Overall hemostasis potential and integrity of the human aortic endothelial barrier. <i>International Journal of Pharmaceutics</i> , 2014, 473, 158-169.	5.2	30
22	Alzheimer’s Disease Phenotype or Inflammatory Insult Does Not Alter Function of L-Type Amino Acid Transporter 1 in Mouse Blood-Brain Barrier and Primary Astrocytes. <i>Pharmaceutical Research</i> , 2019, 36, 17.	3.5	30
23	L-Type Amino Acid Transporter 1 Enables the Efficient Brain Delivery of Small-Sized Prodrug across the Blood-Brain Barrier and into Human and Mouse Brain Parenchymal Cells. <i>ACS Chemical Neuroscience</i> , 2020, 11, 4301-4315.	3.5	30
24	Oral genistein-loaded phytosomes with enhanced hepatic uptake, residence and improved therapeutic efficacy against hepatocellular carcinoma. <i>International Journal of Pharmaceutics</i> , 2021, 601, 120564.	5.2	28
25	Inhibition of the cellular function of perforin by 1-amino-2,4-dicyanopyrido[1,2-a]benzimidazoles. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 4091-4100.	3.0	25
26	Convenient microwave-assisted synthesis of lipophilic sulfenamide prodrugs of metformin. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 624-628.	4.0	24
27	Glutathione-S-transferase selective release of metformin from its sulfonamide prodrug. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 5034-5036.	2.2	23
28	L-Type amino acid transporter 1 (LAT1)-utilizing prodrugs are carrier-selective despite having low affinity for organic anion transporting polypeptides (OATPs). <i>International Journal of Pharmaceutics</i> , 2019, 571, 118714.	5.2	23
29	Diarylthiophenes as inhibitors of the pore-forming protein perforin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016, 26, 355-360.	2.2	22
30	New prodrugs of metformin do not influence the overall haemostasis potential and integrity of the erythrocyte membrane. <i>European Journal of Pharmacology</i> , 2017, 811, 208-221.	3.5	22
31	Mechanistic Study on the Use of the L-Type Amino Acid Transporter 1 for Brain Intracellular Delivery of Ketoprofen via Prodrug: A Novel Approach Supporting the Development of Prodrugs for Intracellular Targets. <i>Molecular Pharmaceutics</i> , 2019, 16, 3261-3274.	4.6	22
32	Biocompatible sulfenamide and sulfonamide derivatives of metformin can exert beneficial effects on plasma haemostasis. <i>Chemico-Biological Interactions</i> , 2018, 280, 15-27.	4.0	21
33	Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2856-2860.	2.2	21
34	Sulfenamide and Sulfonamide Derivatives of Metformin – A New Option to Improve Endothelial Function and Plasma Haemostasis. <i>Scientific Reports</i> , 2019, 9, 6573.	3.3	21
35	Novel Cyclic Phosphate Prodrug Approach for Cytochrome P450-activated Drugs Containing an Alcohol Functionality. <i>Pharmaceutical Research</i> , 2007, 24, 679-687.	3.5	20
36	Sulfenamide and sulfonamide derivatives of metformin can exert anticoagulant and profibrinolytic properties. <i>Chemico-Biological Interactions</i> , 2018, 284, 126-136.	4.0	20

#	ARTICLE	IF	CITATIONS
37	Sulfenamide derivatives can improve transporter-mediated cellular uptake of metformin and induce cytotoxicity in human breast adenocarcinoma cell lines. <i>Bioorganic Chemistry</i> , 2019, 87, 321-334.	4.1	20
38	Structural properties for selective and efficient L-type amino acid transporter 1 (LAT1) mediated cellular uptake. <i>International Journal of Pharmaceutics</i> , 2018, 544, 91-99.	5.2	19
39	Targeted efflux transporter inhibitors – A solution to improve poor cellular accumulation of anti-cancer agents. <i>International Journal of Pharmaceutics</i> , 2018, 550, 278-289.	5.2	19
40	Pharmacoproteomics of Brain Barrier Transporters and Substrate Design for the Brain Targeted Drug Delivery. <i>Pharmaceutical Research</i> , 2022, 39, 1363-1392.	3.5	19
41	Inhibition of the pore-forming protein perforin by a series of aryl-substituted isobenzofuran-1(3H)-ones. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 1319-1336.	3.0	18
42	Metformin and its sulphonamide derivative simultaneously potentiate anti-cholinesterase activity of donepezil and inhibit beta-amyloid aggregation. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2018, 33, 1309-1322.	5.2	18
43	Identification of human, rat and mouse hydrolyzing enzymes bioconverting amino acid ester prodrug of ketoprofen. <i>Bioorganic Chemistry</i> , 2018, 81, 494-503.	4.1	18
44	Astrocyte-Targeted Transporter-Utilizing Derivatives of Ferulic Acid Can Have Multifunctional Effects Ameliorating Inflammation and Oxidative Stress in the Brain. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-13.	4.0	17
45	Pleiotropic Activity of Metformin and Its Sulfonamide Derivatives on Vascular and Platelet Haemostasis. <i>Molecules</i> , 2020, 25, 125.	3.8	17
46	Orchestrated modulation of rheumatoid arthritis via crosstalking intracellular signaling pathways. <i>Inflammopharmacology</i> , 2021, 29, 965-974.	3.9	17
47	Sustained Release of Metformin via Red Blood Cell Accumulated Sulfenamide Prodrug. <i>Journal of Pharmaceutical Sciences</i> , 2014, 103, 2207-2210.	3.3	15
48	Metformin and Its Sulfenamide Prodrugs Inhibit Human Cholinesterase Activity. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-11.	4.0	15
49	Targeting of Perforin Inhibitor into the Brain Parenchyma Via a Prodrug Approach Can Decrease Oxidative Stress and Neuroinflammation and Improve Cell Survival. <i>Molecular Neurobiology</i> , 2020, 57, 4563-4577.	4.0	15
50	Addressing the Biochemical Foundations of a Glucose-Based –Trojan Horse– Strategy to Boron Neutron Capture Therapy: From Chemical Synthesis to <i>In Vitro</i> Assessment. <i>Molecular Pharmaceutics</i> , 2020, 17, 3885-3899.	4.6	15
51	An investigation into the pleiotropic activity of metformin. A glimpse of haemostasis. <i>European Journal of Pharmacology</i> , 2020, 872, 172984.	3.5	15
52	Exploring the Biochemical Foundations of a Successful GLUT1-Targeting Strategy to BNCT: Chemical Synthesis and <i>In Vitro</i> Evaluation of the Entire Positional Isomer Library of <i>ortho</i> -Carboranyl-methyl-Bearing Glucoconjugates. <i>Molecular Pharmaceutics</i> , 2021, 18, 285-304.	4.6	15
53	Towards Metformin Prodrugs. <i>Synthesis</i> , 2008, 2008, 3619-3624.	2.3	14
54	In Vitro and In Vivo Evaluation of a Sulfenamide Prodrug of Basic Metformin. <i>Journal of Pharmaceutical Sciences</i> , 2012, 101, 2854-2860.	3.3	12

#	ARTICLE	IF	CITATIONS
55	Stability of erythrocyte membrane and overall hemostasis potential – A biocompatibility study of mebrofenin and other iminodiacetic acid derivatives. <i>Pharmacological Reports</i> , 2015, 67, 1230-1239.	3.3	12
56	Benzenesulphonamide inhibitors of the cytolytic protein perforin. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 1050-1054.	2.2	12
57	Is metformin a geroprotector? A peek into the current clinical and experimental data. <i>Mechanisms of Ageing and Development</i> , 2020, 191, 111350.	4.6	12
58	Hemocompatible LAT1-inhibitor can induce apoptosis in cancer cells without affecting brain amino acid homeostasis. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2020, 25, 426-440.	4.9	12
59	Improved L-Type amino acid transporter 1 (LAT1)-mediated delivery of anti-inflammatory drugs into astrocytes and microglia with reduced prostaglandin production. <i>International Journal of Pharmaceutics</i> , 2021, 601, 120565.	5.2	12
60	Synthesis and CB1 receptor activities of dimethylheptyl derivatives of 2-arachidonoyl glycerol (2-AG) and 2-arachidonoyl glyceryl ether (2-AGE). <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 2850-2858.	3.0	11
61	Amino acid ester prodrugs conjugated to the α -carboxylic acid group do not display affinity for the L-type amino acid transporter 1 (LAT1). <i>European Journal of Pharmaceutical Sciences</i> , 2015, 66, 36-40.	4.0	10
62	Novel halogenated sulfonamide biguanides with anti-coagulation properties. <i>Bioorganic Chemistry</i> , 2020, 94, 103444.	4.1	10
63	Current Chemical, Biological, and Physiological Views in the Development of Successful Brain-Targeted Pharmaceutics. <i>Neurotherapeutics</i> , 2022, 19, 942-976.	4.4	10
64	Design, Synthesis, and Evaluation of Novel Cyclic Phosphates of 5-Aminosalicylic Acid as Cytochrome P450-Activated Prodrugs. <i>Molecular Pharmaceutics</i> , 2013, 10, 532-537.	4.6	9
65	Biocompatibility Studies of Gadolinium Complexes with Iminodiacetic Acid Derivatives. <i>Biological Trace Element Research</i> , 2019, 189, 426-436.	3.5	9
66	Novel Sulfonamide-Based Analogs of Metformin Exert Promising Anti-Coagulant Effects without Compromising Glucose-Lowering Activity. <i>Pharmaceutics</i> , 2020, 13, 323.	3.8	9
67	Ganciclovir and Its Hemocompatible More Lipophilic Derivative Can Enhance the Apoptotic Effects of Methotrexate by Inhibiting Breast Cancer Resistance Protein (BCRP). <i>International Journal of Molecular Sciences</i> , 2021, 22, 7727.	4.1	8
68	Substituted arylsulphonamides as inhibitors of perforin-mediated lysis. <i>European Journal of Medicinal Chemistry</i> , 2017, 137, 139-155.	5.5	7
69	L-type amino acid transporter 1 (LAT1)-utilizing efflux transporter inhibitors can improve the brain uptake and apoptosis-inducing effects of vinblastine in cancer cells. <i>International Journal of Pharmaceutics</i> , 2020, 586, 119585.	5.2	7
70	L-Type Amino Acid Transporter 1-Utilizing Prodrugs of Ketoprofen Can Efficiently Reduce Brain Prostaglandin Levels. <i>Pharmaceutics</i> , 2020, 12, 344.	4.5	7
71	Molecular characteristics supporting L-Type amino acid transporter 1 (LAT1)-mediated translocation. <i>Bioorganic Chemistry</i> , 2021, 112, 104921.	4.1	7
72	Sulfonamide metformin derivatives induce mitochondrial-associated apoptosis and cell cycle arrest in breast cancer cells. <i>Chemico-Biological Interactions</i> , 2022, 352, 109795.	4.0	7

#	ARTICLE	IF	CITATIONS
73	Generation 2 (G2) â€“ Generation 4 (G4) PAMAM dendrimers disrupt key plasma coagulation parameters. <i>Toxicology in Vitro</i> , 2019, 59, 87-99.	2.4	6
74	Neurosteroids: Structure-Uptake Relationships and Computational Modeling of Organic Anion Transporting Polypeptides (OATP)1A2. <i>Molecules</i> , 2021, 26, 5662.	3.8	6
75	Species differences in the intra-brain distribution of an L-type amino acid transporter 1 (LAT1) -utilizing compound between mice and rats. <i>International Journal of Pharmaceutics</i> , 2021, 596, 120300.	5.2	5
76	Structural Comparison of Sulfonamide-Based Derivatives That Can Improve Anti-Coagulation Properties of Metformin. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4132.	4.1	5
77	Comparison of Experimental Strategies to Study I-Type Amino Acid Transporter 1 (LAT1) Utilization by Ligands. <i>Molecules</i> , 2022, 27, 37.	3.8	5
78	Efficient Strategy to Prepare Water-Soluble Prodrugs of Ketones. <i>Synlett</i> , 2006, 2006, 0701-0704.	1.8	4
79	Hemocompatible L-Type amino acid transporter 1 (LAT1)-Utilizing prodrugs of perforin inhibitors can accumulate into the pancreas and alleviate inflammation-induced apoptosis. <i>Chemico-Biological Interactions</i> , 2021, 345, 109560.	4.0	4
80	Increased/Targeted Brain (Pro)Drug Delivery via Utilization of Solute Carriers (SLCs). <i>Pharmaceutics</i> , 2022, 14, 1234.	4.5	3